A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS
Status:
Terminated
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This study is intended to determine the safety and maximum tolerated dose of a drug, OXi4503
(combretastatin A1 diphosphate, CA1P, OXiGENE), in patients with relapsed and refractory AML
and MDS.